Monitoring ovarian cancer: CA125 trial stirs controversy.
Chitale
Radha
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001007:Anxiety / Q000209:etiology*; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D015986:Confounding Factors, Epidemiologic; D005060:Europe; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D011159:Population Surveillance / Q000379:methods*; D011237:Predictive Value of Tests; D011379:Prognosis; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012107:Research Design; D013315:Stress, Psychological / Q000209:etiology*; D011795:Surveys and Questionnaires; D016019:Survival Analysis; D013997:Time Factors
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen